Last reviewed 2026-05-19 · How we verify

topical tetracycline

topical tetracycline is a Tetracycline antibiotic Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved for Bacterial skin infections (acne, impetigo, infected wounds), Topical prophylaxis and treatment of superficial skin infections.

Topical tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, reducing microbial growth on the skin surface.

Topical tetracycline is used to treat conditions such as acne vulgaris, diabetic foot ulcers, and trichiasis, as well as to prevent surgical site infections in head and neck cancer patients. It works by inhibiting the bacterial 70S ribosome, a mechanism that is characteristic of its classification as a small molecule inhibitor.

At a glance

Mechanism of action

Tetracycline is a broad-spectrum antibiotic that penetrates bacterial cells and binds reversibly to the 30S ribosomal subunit, blocking aminoacyl-tRNA from entering the A site and preventing peptide bond formation. When applied topically, it achieves high local concentrations at the site of infection or inflammation while minimizing systemic absorption. This mechanism makes it effective against a wide range of gram-positive and gram-negative bacteria commonly found in skin infections.

Approved indications

• Bacterial skin infections (acne, impetigo, infected wounds)
• Topical prophylaxis and treatment of superficial skin infections

Common side effects

• Local skin irritation or erythema
• Photosensitivity (rare with topical formulation)
• Allergic contact dermatitis

Key clinical trials

• The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
• Effects of Treatments on Atopic Dermatitis (PHASE2)
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
• Topical Minocycline for CARP (EARLY_PHASE1)
• Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne (PHASE4)
• STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
• Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
• Analysis of the Microbiome in Rosacea (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• topical tetracycline CI brief — competitive landscape report
• topical tetracycline updates RSS · CI watch RSS
• Johns Hopkins University portfolio CI

Frequently asked questions about topical tetracycline

Related

• Drug class: All Tetracycline antibiotic drugs
• Target: All drugs targeting Bacterial 30S ribosomal subunit
• Manufacturer: Johns Hopkins University — full pipeline
• Therapeutic area: All drugs in Dermatology / Infectious Disease
• Indication: Drugs for Bacterial skin infections (acne, impetigo, infected wounds)
• Indication: Drugs for Topical prophylaxis and treatment of superficial skin infections

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing